Capricor Therapeutics, Inc. (FRA:4LN2)

Capricor Therapeutics Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 9, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	1,060	606	136	89	62	57
Market Cap Growth	71.53%	344.91%	52.69%	43.40%	8.51%	952.19%
Enterprise Value	988	526	113	46	26	29
Last Close Price	21.00	13.16	4.37	3.53	2.56	3.06
PS Ratio	111.74	28.18	5.98	37.37	288.92	226.06
PB Ratio	14.83	4.31	6.66	8.09	2.26	2.49
P/TBV Ratio	14.83	4.31	6.66	8.09	2.26	2.49
P/FCF Ratio	-	-	-	61.25	-	-
P/OCF Ratio	-	-	-	19.39	-	-
EV/Sales Ratio	103.22	24.43	4.94	19.10	122.30	113.31
EV/FCF Ratio	-16.95	-	-	31.31	-	-
Debt / Equity Ratio	0.17	0.01	0.10	0.22	0.09	0.01
Debt / FCF Ratio	-	-	-	1.64	-	-
Asset Turnover	0.10	0.19	0.46	0.06	0.01	0.01
Quick Ratio	3.50	7.70	1.59	1.78	8.54	11.01
Current Ratio	3.59	7.77	1.63	1.82	8.82	11.33
Return on Equity (ROE)	-107.79%	-48.16%	-129.63%	-134.49%	-67.23%	-77.95%
Return on Assets (ROA)	-49.39%	-23.21%	-27.66%	-40.60%	-34.46%	-37.42%
Return on Capital (ROIC)	-64.37%	-30.98%	-76.81%	-76.41%	-41.71%	-48.40%
Return on Capital Employed (ROCE)	-88.20%	-28.50%	-87.70%	-112.00%	-56.30%	-43.30%
Earnings Yield	-6.59%	-6.45%	-14.80%	-30.43%	-28.30%	-19.47%
FCF Yield	-5.50%	-6.62%	-18.36%	1.63%	-25.45%	-15.12%
Buyback Yield / Dilution	-43.02%	-31.52%	-9.06%	-6.34%	-48.28%	-319.55%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.